- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 939-953 of
973 results
1038 Exhibit: Seino 2008
Document
IPR2023-00724, No. 1038 Exhibit - Seino 2008 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
1043 Exhibit: US20040102486
Document
IPR2023-00724, No. 1043 Exhibit - US20040102486 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
2487 Exhibit: EX2487 US Patent No 8,129,343
Document
IPR2023-00724, No. 2487 Exhibit - EX2487 US Patent No 8,129,343 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2474 Exhibit: EX2474 US Food Drug Administration, DrugsFDA, Mounjaro
Document
IPR2023-00724, No. 2474 Exhibit - EX2474 US Food Drug Administration, DrugsFDA, Mounjaro (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2505 Exhibit: EX2505 Novo Nordisk, Financial report for the period 1 January 2020...
Document
IPR2023-00724, No. 2505 Exhibit - EX2505 Novo Nordisk, Financial report for the period 1 January 2020 to 31 December 2020 Feb 3, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2390 Exhibit: EX2390 Usherwood, T, Encouraging adherence to long term medicat...
Document
IPR2023-00724, No. 2390 Exhibit - EX2390 Usherwood, T, Encouraging adherence to long term medication, Aust Prescr, 2017 Aug 404147 150 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2430 Exhibit: EX2430 Oseni® Prescribing Information rev Dec 2017
Document
IPR2023-00724, No. 2430 Exhibit - EX2430 Oseni® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2446 Exhibit: EX2446 Trulicity® Prescribing Information rev June 2018
Document
IPR2023-00724, No. 2446 Exhibit - EX2446 Trulicity® Prescribing Information rev June 2018 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1116 Exhibit: Exhibit 1116 Mounjaro label
Document
IPR2023-00724, No. 1116 Exhibit - Exhibit 1116 Mounjaro label (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2462 Exhibit: EX2462 US Food Drug Administration, DrugsFDA, Qtern
Document
IPR2023-00724, No. 2462 Exhibit - EX2462 US Food Drug Administration, DrugsFDA, Qtern (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2524 Exhibit: EX2524 Eli Lilly Co, 2019 Financial Report
Document
IPR2023-00724, No. 2524 Exhibit - EX2524 Eli Lilly Co, 2019 Financial Report (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1142 Exhibit: Exhibit 1142 Radbill
Document
IPR2023-00724, No. 1142 Exhibit - Exhibit 1142 Radbill (P.T.A.B. May. 22, 2024)
|
|
Cite Document
... PhD Regarding Inva lidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122...
Document
IPR2023-00724, No. 2551 Exhibit - EX2551 Opening Expert Report of William J Jusko, PhD Regarding Inva lidity of US Patent No 10,335,462, In re Ozempic Semaglutide Patent Litigation, No 122 cv 03038
|
|
Cite Document
2653 Exhibit: EX2653 July 8, 2024 Email Thread Among Counsel for Petitioners My...
Document
IPR2023-00724, No. 2653 Exhibit - EX2653 July 8, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft p...
|
|
Cite Document
2084 Exhibit: EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly...
Document
IPR2023-00724, No. 2084 Exhibit - EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes SUSTAIN 7 a randomized, open label, phase 3b trial,” La...
|
|
Cite Document
